BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- US stock futures mixed as Apple slides, midterms loom
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 57.44 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $57.44 | 52 Week High | $108.96 | |||
| Open | $57.44 | 52 Week Low | $62.12 | |||
| Day High | $57.44 | P/E | N/A | |||
| Day Low | $57.44 | EPS | $-1.27 | |||
| Volume | 277 | |||||
